Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SGN 1

Next Previous
Drug Profile

SGN 1

Alternative Names: SalMet-Vec; SGN-1

Latest Information Update: 28 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Guangzhou Huajin Pharmaceutical
  • Developer Guangzhou Sinogen Pharmaceutical
  • Class Antineoplastics; Bacteria
  • Mechanism of Action Bacteria replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Breast cancer; Head and neck cancer; Liver cancer; Pancreatic cancer; Sarcoma
  • No development reported Cancer

Most Recent Events

  • 28 Sep 2023 No recent reports of development identified for clinical-Phase-Unknown development in Cancer(Late-stage disease, Second-line therapy or greater) in China (Intratumoural)
  • 28 Sep 2023 No recent reports of development identified for clinical-Phase-Unknown development in Cancer(Late-stage disease, Second-line therapy or greater) in China (IV, Infusion)
  • 02 Jun 2023 Pharmacodynamics and adverse events data from a preclinical trial in Cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top